John Teerlink, MD

Professor

Dr. John R. Teerlink, F.A.C.C., F.A.H.A., F.E.S.C., F.H.F.A., F.H.F.S.A., F.R.C.P.(UK) is Director of Heart Failure and of the Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center in San Francisco, California. He graduated from Swarthmore College with Highest Honors in Comparative Religious Studies and Cellular Biology. After receiving his medical degree from Harvard Medical School, where he performed a year of research in the laboratory of Drs. Janice and Marc Pfeffer, he completed an internal medicine residency at the University of California San Francisco (UCSF). He continued his basic science training through a post-doctoral research fellowship at Hoffman-LaRoche in Basel, Switzerland with Drs. Martine and Jean-Paul Clozel. Dr. Teerlink completed his cardiovascular medicine fellowship and a Howard Hughes post-doctoral research fellowship at UCSF, subsequently joining the faculty, where he currently is a Professor of Clinical Medicine.

He is actively involved in the design and execution of many acute and chronic heart failure clinical trials, serving on endpoint, data safety monitoring, and steering committees for numerous international studies investigating a variety of new therapies, including tezosentan (RITZ program, VERITAS), levosimendan (REVIVE 1&2), nesiritide (ASCEND-HF), serelaxin (Pre-RELAX-AHF, RELAX-AHF, RELAX-AHF-2, RELAX-ASIA, RELAX-Repeat), rolofylline (PROTECT), omecamtiv mecarbil (CY1111, CY1121, ATOMIC-AHF, COSMIC-HF, GALACTIC-HF, METEORIC-HF), TRV027 (BLAST-AHF), warfarin/ clopidogrel/ aspirin (WATCH, WARCEF), nitroxyl donor (STANDUP-AHF), fineranone (FIGARRO, FIDELIO), LCZ696 (sacubitril/ valsartan; PARADIGM-HF), and empagliflozin (EMPEROR-Preserved, EMPEROR-Reduced, DINAMO), as well as stem cell therapies (CHART-1) and diagnostic modalities, such as CardioMEMS device (CHAMPION, CardioMEMS Post-approval Study), left atrial pressure sensor (LAPTOP-HF) and other devices (ADAPT-Response). He serves as a consultant on clinical development programs in multiple areas of cardiology, as well as in cardiovascular safety for non-cardiovascular indications.

Dr. Teerlink has been an active member of the Heart Failure Society of America, serving on many committees including the Membership, Scientific Program, Corporate Affairs, Development, Lifetime Achievement Award and Guideline Committees and currently serves as Secretary and on the Board of Directors and the Executive Council. He also currently serves on the Acute Heart Failure Committee of the European Society of Cardiology Heart Failure Association and has served on the National Committee on Heart Failure and Transplantation of the American Heart Association. He is a founding and charter member of the American Association of Heart Failure Nurses. Dr. Teerlink completed a four-year term as a permanent member of the United States Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee, and frequently serves as an ad hoc member of multiple other FDA advisory committees and panels for medical devices, diagnostics, biologics and drugs. He is a member of the joint FDA/ Duke University Standardized Data Collection for Cardiovascular Clinical Trials Initiative to develop standardized definitions for cardiovascular endpoints. He was an Associate Editor for the Journal of Cardiac Failure, is currently the Guest Editor-in-Chief for JACC: Heart Failure, and is a clinical scholar presenting many lectures and publications, including a chapter on Acute Heart Failure in Braunwald’s Heart Disease textbook. He was profiled in The Lancet as an internationally recognized leader in heart failure.

Education
Clinical Cardiology Fellowship, 1995 - Cardiovascular Medicine, University of California, San Francisco
Post-Doctoral Fellowship, 1993 - Cardiovascular Pharmacology, F. Hoffmann-La Roche, LTD (Basel, Switzerland
Internal Medicine Residency, 1991 - Internal Medicine, University of California, San Francisco
M.D., 1988 - Medicine, Harvard Medical School
BA with Highest Honors, 1983 - Comparative Religious Studies/ Cellular and Molecular Biology, Swarthmore College
Honors and Awards
  • UCSF Clinical Cardiology Fellow’s Teaching Award, UCSF, 2010
  • Advisory Committee Service Award, United States Food and Drug Administration, 2008
  • Veterans Affairs Young Investigators Research Award, Department of Veterans Affairs, VISN 21, 2000
  • Alpha Omega Alpha Nominee, Outstanding House Officer Teacher, UCSF, 1995
  • Alpha Omega Alpha Nominee, Outstanding House Officer Teacher, UCSF, 1990
  • Medical Student Research Fellowship Award, American Heart Association/ Harvard Medical School, 1986-1987
  • Holmes Prize in Religion, Swarthmore College, 1983
  • Phi Beta Kappa, Swarthmore College, 1983
  • Holmes Prize in Religion, Swarthmore College, 1981
Publications
  1. Metra M, Pagnesi M, Claggett BL, Díaz R, Felker GM, McMurray JJV, Solomon SD, Bonderman D, Fang JC, Fonseca C, Goncalvesova E, Howlett JG, Li J, O'Meara E, Miao ZM, Abbasi SA, Heitner SB, Kupfer S, Malik FI, Teerlink JR. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. 2022. PMID: 35675469


  2. DeFilippis EM, Echols M, Adamson PB, Batchelor WB, Cooper LB, Cooper LS, Desvigne-Nickens P, George RT, Ibrahim NE, Jessup M, Kitzman DW, Leifer ES, Mendoza M, Piña IL, Psotka M, Senatore FF, Stein KM, Teerlink JR, Yancy CW, Lindenfeld J, Fiuzat M, O'Connor CM, Vardeny O, Vaduganathan M. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. 2022. PMID: 35319725


  3. Konstam MA, Mann DL, Udelson JJE, Ardell JL, De Ferrari GM, Cowie MR, Klein HU, Gregory DD, Massaro JM, Libbus I, DiCarlo LA, Butler J, Parker JD, Teerlink JR. Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure. 2022. PMID: 35530511


  4. Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, Comin-Colet J, Ferreira JP, Mentz RJ, Nassif ME, Psotka MA, Tromp J, Brueckmann M, Blatchford JP, Salsali A, Voors AA. Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized for Acute Heart Failure - Results From the EMPULSE Trial. 2022. PMID: 35377706


  5. Solomon SD, Claggett BL, Miao ZM, Diaz R, Felker GM, McMurray JJV, Metra M, Corbalan R, Filippatos G, Goudev AR, Mareev V, Serpytis P, Suter T, Yilmaz MB, Zannad F, Kupfer S, Heitner SB, Malik FI, Teerlink JR. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. 2022. PMID: 35325102


  6. Lewis GD, Docherty KF, Voors AA, Cohen-Solal A, Metra M, Whellan DJ, Ezekowitz JA, Ponikowski P, Böhm M, Teerlink JR, Heitner SB, Kupfer S, Malik FI, Meng L, Felker GM. Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. 2022. PMID: 35236099


  7. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. 2022. PMID: 35228754


  8. Grand J, Miger K, Sajadieh A, Køber L, Torp-Pedersen C, Ertl G, López-Sendón J, Pietro Maggioni A, Teerlink JR, Sato N, Gimpelewicz C, Metra M, Holbro T, Nielsen OW. Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. 2022. PMID: 35184572


  9. Fiuzat M, Hamo CE, Butler J, Abraham WT, DeFilippis EM, Fonarow GC, Lindenfeld J, Mentz RJ, Psotka MA, Solomon SD, Teerlink JR, Vaduganathan M, Vardeny O, McMurray JJV, O'Connor CM. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. 2022. PMID: 35115106


  10. Allen LA, Teerlink JR, Gottlieb SS, Ahmad T, Lam CSP, Psotka MA. Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. 2022. PMID: 35000432


  11. Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M, Anand I, Crespo-Leiro MG, Dahlström U, Goncalvesova E, Howlett JG, MacDonald P, Parkhomenko A, Tomcsányi J, Abbasi SA, Heitner SB, Hucko T, Kupfer S, Malik FI, Teerlink JR. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. 2021. PMID: 34643642


  12. Emmens JE, Ter Maaten JM, Matsue Y, Figarska SM, Sama IE, Cotter G, Cleland JGF, Davison BA, Felker GM, Givertz MM, Greenberg B, Pang PS, Severin T, Gimpelewicz C, Metra M, Voors AA, Teerlink JR. Worsening renal function in acute heart failure in the context of diuretic response. 2021. PMID: 34786794


  13. Ameri P, Bertero E, Maack C, Teerlink JR, Rosano G, Metra M. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment? 2021. PMID: 34037742


  14. Matsue Y, Sama IE, Postmus D, Metra M, Greenberg BH, Cotter G, Davison BA, Felker GM, Filippatos G, Pang P, Ponikowski P, Severin T, Gimpelewicz C, Voors AA, Teerlink JR. Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. 2021. PMID: 34627724


  15. Rosano GMC, Allen LA, Abdin A, Lindenfeld J, O'Meara E, Lam CSP, Lancellotti P, Savarese G, Gottlieb SS, Teerlink J, Wintrich J, Böhm M. Drug Layering in Heart Failure: Phenotype-Guided Initiation. 2021. PMID: 34627725


  16. Grand J, Miger K, Sajadieh A, Køber L, Torp-Pedersen C, Ertl G, López-Sendón J, Pietro Maggioni A, Teerlink JR, Sato N, Gimpelewicz C, Metra M, Holbro T, Nielsen OW. Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. 2021. PMID: 34514815


  17. Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD, EMPEROR-Preserved Trial Study Group. Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial. 2021. PMID: 34459213


  18. Psotka MA, O'Connor CM, Teerlink JR. Empower the Future… Even Oprah Had a Mentor! 2021. PMID: 34325891


  19. Cleland JGF, Pfeffer MA, Clark AL, Januzzi JL, McMurray JJV, Mueller C, Pellicori P, Richards M, Teerlink JR, Zannad F, Bauersachs J. The struggle towards a Universal Definition of Heart Failure-how to proceed? 2021. PMID: 33791787


  20. Cotter G, Davison BA, Edwards C, Senger S, Teerlink JR, Zannad F, Nielsen OW, Metra M, Mebazaa A, Chioncel O, Greenberg BH, Maggioni AP, Ertl G, Sato N, Cohen-Solal A. Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. 2021. PMID: 34107289


  21. Teerlink JR, Felker GM, McMurray JJV. Omecamtiv Mecarbil in Systolic Heart Failure. Reply. 2021. PMID: 34010541


  22. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Biering-Sørensen T, Böhm M, Bonderman D, Fang JC, Lanfear DE, Lund M, Momomura SI, O'Meara E, Ponikowski P, Spinar J, Flores-Arredondo JH, Claggett BL, Heitner SB, Kupfer S, Abbasi SA, Malik FI, GALACTIC-HF Investigators. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. 2021. PMID: 34015475


  23. Biering-Sørensen T, Minamisawa M, Liu J, Claggett B, Papolos AI, Felker GM, McMurray JJV, Legg JC, Malik FI, Honarpour N, Kurtz CE, Teerlink JR, Solomon SD. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). 2021. PMID: 33826209


  24. Ravera A, Santema BT, Sama IE, Meyer S, Lombardi CM, Carubelli V, Ferreira JP, Lang CC, Dickstein K, Anker SD, Samani NJ, Zannad F, van Veldhuisen DJ, Teerlink JR, Metra M, Voors AA. Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. 2021. PMID: 33728762


  25. Alhakak AS, Teerlink JR, Lindenfeld J, Böhm M, Rosano GMC, Biering-Sørensen T. The Significance of Left Ventricular Ejection Time in Heart Failure with Reduced Ejection Fraction. 2021. PMID: 33590579


  26. Tromp J, Ponikowski P, Salsali A, Angermann CE, Biegus J, Blatchford J, Collins SP, Ferreira JP, Grauer C, Kosiborod M, Nassif ME, Psotka MA, Brueckmann M, Teerlink JR, Voors AA. SGLT2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. 2021. PMID: 33609072


  27. Lang NN, Ahmad FA, Cleland JG, O'Connor CM, Teerlink JR, Voors AA, Taubel J, Hodes AR, Anwar M, Karra R, Sakata Y, Ishihara S, Senior R, Khemka A, Prasad NG, DeSouza MM, Seiffert D, Ye JY, Kessler PD, Borentain M, Solomon SD, Felker GM, McMurray JJV. Hemodynamic Effects of the Nitroxyl Donor Cimlanod (BMS-986231) in Chronic Heart Failure: A Randomized Trial. 2021. PMID: 33620131


  28. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Felker GM, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Piepoli MF, Ponikowski P, Rosano GMC, Sakata Y, Seferovic P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition o 2021. PMID: 33605000


  29. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Felker GM, Filippatos G, Fonarow GC, Fiuzat M, Gomez-Mesa JE, Heidenreich P, Imamura T, Januzzi J, Jankowska EA, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, SeferoviC P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition o 2021. PMID: 33663906


  30. Clarke JD, Riello R, Allen LA, Psotka MA, Teerlink JR, Lindenfeld J, Desai NR, Ahmad T. Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure: A Review of Published Clinical Trials. 2021. PMID: 33530705


  31. Markousis-Mavrogenis G, Tromp J, Mentz RJ, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P. The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. 2021. PMID: 33497808


  32. Bhatt AS, Abraham WT, Lindenfeld J, Bristow M, Carson PE, Felker GM, Fonarow GC, Greene SJ, Psotka MA, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Wittes J, Fiuzat M, O'Connor CM, Butler J. Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 2020. PMID: 33309582


  33. Felker GM, McMurray JJV, Cleland JG, O'Connor CM, Teerlink JR, Voors AA, Belohlavek J, Böhm M, Borentain M, Bueno H, Cole RT, DeSouza MM, Ezekowitz JA, Filippatos G, Lang NN, Kessler PD, Martinez FA, Mebazaa A, Metra M, Mosterd A, Pang PS, Ponikowski P, Sato N, Seiffert D, Ye J. Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study. 2020. PMID: 33248986


  34. Psotka MA, Abraham WT, Fiuzat M, Filippatos G, Lindenfeld J, Ahmad T, Bhatt AS, Carson PE, Cleland JGF, Felker GM, Januzzi JL, Kitzman DW, Leifer ES, Lewis EF, McMurray JJV, Mentz RJ, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Vardeny O, Whellan DJ, Wittes J, Anker SD, O'Connor CM. Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. 2020. PMID: 33183511


  35. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. 2020. PMID: 33185990


  36. Abraham WT, Psotka MA, Fiuzat M, Filippatos G, Lindenfeld J, Mehran R, Ambardekar AV, Carson PE, Jacob R, Januzzi JL, Konstam MA, Krucoff MW, Lewis EF, Piccini JP, Solomon SD, Stockbridge N, Teerlink JR, Unger EF, Zeitler EP, Anker SD, O'Connor CM. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. 2020. PMID: 33199251


  37. Abraham WT, Psotka MA, Fiuzat M, Filippatos G, Lindenfeld J, Mehran R, Ambardekar AV, Carson PE, Jacob R, Januzzi JL, Konstam MA, Krucoff MW, Lewis EF, Piccini JP, Solomon SD, Stockbridge N, Teerlink JR, Unger EF, Zeitler EP, Anker SD, O'Connor CM. Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. 2020. PMID: 33017862


  38. Biering-Sørensen T, Minamisawa M, Claggett B, Liu J, Felker GM, McMurray JJV, Malik FI, Abbasi S, Kurtz CE, Teerlink JR, Solomon SD. Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. 2020. PMID: 33176443


  39. Felker GM, Solomon SD, McMurray JJV, Cleland JGF, Abbasi SA, Malik FI, Zhang H, Globe G, Teerlink JR. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients with Chronic Heart Failure: Results from the COSMIC-HF Study. 2020. PMID: 33176437


  40. Loungani RS, Teerlink JR, Metra M, Allen LA, Butler J, Carson PE, Chen CW, Cotter G, Davison BA, Eapen ZJ, Filippatos GS, Gimpelewicz C, Greenberg B, Holbro T, Januzzi JL, Lanfear DE, Pang PS, Piña IL, Ponikowski P, Miller AB, Voors AA, Felker GM. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. 2020. PMID: 33189635


  41. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE,. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. 2020. PMID: 32985088


  42. Bartunek J, Terzic A, Davison BA, Behfar A, Sanz-Ruiz R, Wojakowski W, Sherman W, Heyndrickx GR, Metra M, Filippatos GS, Waldman SA, Teerlink JR, Henry TD, Gersh BJ, Hajjar R, Tendera M, Senger S, Cotter G, Povsic TJ, Wijns W. Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. 2020. PMID: 33094909


  43. Alhakak AS, Sengeløv M, Jørgensen PG, Bruun NE, Johnsen C, Abildgaard U, Iversen AZ, Hansen TF, Teerlink JR, Malik FI, Solomon SD, Gislason G, Biering-Sørensen T. Left ventricular systolic ejection time is an independent predictor of all-cause mortality in heart failure with reduced ejection fraction. 2020. PMID: 33034122


  44. Packer M, Anker SD, Butler J, Filippatos GS, Ferreira JP, Pocock S, Carson PE, Anand IS, Doehner W, Haass M, Komajda M, Miller AB, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F. Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. 2020. PMID: 33081531


  45. Feng S, Janwanishstaporn S, Teerlink JR, Metra M, Cotter G, Davison B, Felker GM, Filippatos G, Pang P, Ponikowski P, Sama IE, Voors AA, Greenberg B. Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study. 2020. PMID: 32964537


  46. Davison BA, Cotter G, Filippatos GS, Zannad F, Voors AA, Metra M, Teerlink JR, Senger S, Mebazaa A, Greenberg B. Drug development in oncology and devices-lessons for heart failure drug development and approval? a review. 2020. PMID: 32939666


  47. Psotka MA, Fiuzat M, Solomon SD, Chauhan C, Felker GM, Butler J, Teerlink JR, Sinha SS, O'Connor CM, Konstam MA. Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. 2020. PMID: 32833519


  48. Anker SD, Butler J, Khan MS, Abraham WT, Bauersachs J, Bocchi E, Bozkurt B, Braunwald E, Chopra VK, Cleland JG, Ezekowitz J, Filippatos G, Friede T, Hernandez AF, Lam CSP, Lindenfeld J, McMurray JJV, Mehra M, Metra M, Packer M, Pieske B, Pocock SJ, Ponikowski P, Rosano GMC, Teerlink JR, Tsutsui H, Van Veldhuisen DJ, Verma S, Voors AA, Wittes J, Zannad F, Zhang J, Seferovic P, Coats AJS. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 2020. PMID: 32498081


  49. Psotka MA, Teerlink JR. Assessing the lifetime benefit of heart failure therapies. 2020. PMID: 32446325


  50. Harjola VP, Parissis J, Bauersachs J, Brunner-La Rocca HP, Bueno H, Celutkiene J, Chioncel O, Coats AJS, Collins SP, de Boer RA, Filippatos G, Gayat E, Hill L, Laine M, Lassus J, Lommi J, Masip J, Mebazaa A, Metra M, Miró Ò, Mortara A, Mueller C, Mullens W, Peacock WF, Pentikäinen M, Piepoli MF, Polyzogopoulou E, Rudiger A, Ruschitzka F, Seferovic P, Sionis A, Teerlink JR, Thum T, Varpula M, Weinstein JM, Yilmaz MB. Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. 2020. PMID: 32347648


  51. Fiuzat M, Lowy N, Stockbridge N, Sbolli M, Latta F, Lindenfeld J, Lewis EF, Abraham WT, Teerlink J, Walsh M, Heidenreich P, Bozkurt B, Starling RC, Solomon S, Felker GM, Butler J, Yancy C, Stevenson LW, O'Connor C, Unger E, Temple R, McMurray J. Endpoints in Heart Failure Drug Development: History and Future. 2020. PMID: 32278679


  52. Davison BA, Takagi K, Senger S, Koch G, Metra M, Kimmoun A, Mebazaa A, Voors AA, Nielsen OW, Chioncel O, Pang PS, Greenberg BH, Maggioni AP, Cohen-Solal A, Ertl G, Sato N, Teerlink JR, Filippatos G, Ponikowski P, Gayat E, Edwards C, Cotter G. Mega-trials in heart failure: effects of dilution in examination of new therapies. 2020. PMID: 32227620


  53. Janwanishstaporn S, Feng S, Teerlink J, Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Pang P, Ponikowski P, Severin T, Gimpelewicz C, Holbro T, Chen CW, Sama I, Voors AA, Greenberg BH. Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial. 2020. PMID: 32141161


  54. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg JC, Büchele G, Varin C, Kurtz CE, Malik FI, Honarpour N. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. 2020. PMID: 32035892


  55. Anand IS, Konstam MA, Klein HU, Mann DL, Ardell JL, Gregory DD, Massaro JM, Libbus I, DiCarlo LA, Udelson JJE, Butler J, Parker JD, Teerlink JR. Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. 2020. PMID: 31984682


  56. Carubelli V, Zhang Y, Metra M, Lombardi C, Felker GM, Filippatos G, O'Connor CM, Teerlink JR, Simmons P, Segal R, Malfatto G, La Rovere MT, Li D, Han X, Yuan Z, Yao Y, Li B, Lau LF, Bianchi G, Zhang J. Treatment with 24?hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. 2020. PMID: 31975496


  57. Teerlink JR, Davison BA, Cotter G, Maggioni AP, Sato N, Chioncel O, Ertl G, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Edwards C, Senger S, Teichman SL, Nielsen OW, Voors AA, Metra M. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. 2019. PMID: 31886953


  58. Butler J, Packer M, Greene SJ, Fiuzat M, Anker SD, Anstrom KJ, Carson PE, Cooper LB, Fonarow GC, Hernandez AF, Januzzi JL, Jessup M, Kalyani RR, Kaul S, Kosiborod M, Lindenfeld J, McGuire DK, Sabatine MS, Solomon SD, Teerlink JR, Vaduganathan M, Yancy CW, Stockbridge N, O'Connor CM. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. 2019. PMID: 31841369


  59. Pandhi P, Ter Maaten JM, Emmens JE, Struck J, Bergmann A, Cleland JG, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Cotter G, Davison B, van Veldhuisen DJ, Voors AA. Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. 2019. PMID: 31797505


  60. Lee TC, Qian M, Liu Y, Graham S, Mann DL, Nakanishi K, Teerlink JR, Lip GYH, Freudenberger RS, Sacco RL, Mohr JP, Labovitz AJ, Ponikowski P, Lok DJ, Matsumoto K, Estol C, Anker SD, Pullicino PM, Buchsbaum R, Levin B, Thompson JLP, Homma S, Di Tullio MR. Cognitive Decline Over Time in Patients With Systolic Heart Failure: Insights From WARCEF. 2019. PMID: 31779926


  61. Konstam MA, Udelson JE, Butler J, Klein HU, Parker JD, Teerlink JR, Wedge PM, Saville BR, Ardell JL, Libbus I, DiCarlo LA. Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HFrEF Pivotal Study Design. 2019. PMID: 31722536


  62. Rachwan RJ, Butler J, Collins SP, Cotter G, Davison BA, Senger S, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Teerlink JR, Voors AA, de Boer RA, Soergel DG, Felker GM, Pang PS. Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. 2019. PMID: 31646707


  63. Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Ouwerkerk W, van Veldhuisen DJ, Voors AA, van der Meer P. Hyperkalemia and Treatment With RAAS-Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. 2019. PMID: 31606364


  64. Biegus J, Demissei B, Postmus D, Cotter G, Davison BA, Felker GM, Filippatos G, Gimpelewicz C, Greenberg B, Metra M, Severin T, Teerlink JR, Voors AA, Ponikowski P. Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. 2019. PMID: 31568696


  65. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Voors AA, Adams KF, Anker SD, Arias-Mendoza A, Avendaño P, Bacal F, Böhm M, Bortman G, Cleland JGF, Cohen-Solal A, Crespo-Leiro MG, Dorobantu M, Echeverría LE, Ferrari R, Goland S, Goncalvesová E, Goudev A, Køber L, Lema-Osores J, Levy PD, McDonald K, Manga P, Merkely B, Mueller C, Pieske B, Silva-Cardoso J, Špinar J, Squire I, Stepinska J, Van Mieghem W, von Lewinski D, Wikström G, Yilmaz MB, Hagner N, Holbro T, Hua TA, Sabarwal SV, Severin T, Szecsödy P, Gimpelewicz C. Effects of Serelaxin in Patients with Acute Heart Failure. 2019. PMID: 31433919


  66. Ahmad T, Miller PE, McCullough M, Desai NR, Riello R, Psotka M, Böhm M, Allen LA, Teerlink JR, Rosano GMC, Lindenfeld J. Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. 2019. PMID: 31407860


  67. Psotka MA, Fiuzat M, Carson PE, Kao DP, Cerkvenik J, Schaber DE, Verta P, Kazmierski RT, Shinnar M, Stockbridge N, Unger EF, Zuckerman B, Butler J, Felker GM, Konstam MA, Lindenfeld J, Solomon SD, Teerlink JR, O'Connor CM, Abraham WT. Design of a "Lean" Case Report Form for Heart Failure Device Development. 2019. PMID: 31401097


  68. Beldhuis IE, Streng KW, van der Meer P, Maaten JMT, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Cotter G, Cleland JGF, Davison BA, Givertz MM, Teerlink JR, Bloomfield DM, Voors AA, Damman K. Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. 2019. PMID: 31319165


  69. Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, O'Connor CM, Seiffert D, Teerlink JR, Voors AA, McMurray JJV. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. 2019. PMID: 31168885


  70. Psotka MA, Gottlieb SS, Francis GS, Allen LA, Teerlink JR, Adams KF, Rosano GMC, Lancellotti P. Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week. 2019. PMID: 31072579


  71. Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, O'Connor CM, Teerlink JR, Zannad F, Solomon SD. Erratum to 'The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions' [Eur J Heart Fail 2018;20:963-972]. 2019. PMID: 31222927


  72. Psotka MA, Ammon SE, Fiuzat M, Bozkurt B, Chung ES, Cole RT, Greene SJ, Kraus D, Ky B, McIlvennan CK, Shah P, Teerlink JR, Walsh MN, Jessup M, O'Connor CM. Heart Failure Site-Based Research in the United States: Results of the Heart Failure Society of America Research Network Survey. 2019. PMID: 30981742


  73. Lee TC, Qian M, Mu L, Di Tullio MR, Graham S, Mann DL, Nakanishi K, Teerlink JR, Lip GYH, Freudenberger RS, Sacco RL, Mohr JP, Labovitz AJ, Ponikowski P, Lok DJ, Estol C, Anker SD, Pullicino PM, Buchsbaum R, Levin B, Thompson JLP, Homma S, Ye S. Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. 2019. PMID: 30816013


  74. Shah N, Qian M, Di Tullio MR, Graham S, Mann DL, Sacco RL, Lip GYH, Labovitz AJ, Ponikowski P, Lok DJ, Anker SD, Teerlink JR, Thompson JLP, Homma S, Freudenberger RS. Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction. 2019. PMID: 30801690


  75. Greene SJ, Mentz RJ, Fiuzat M, Butler J, Solomon SD, Ambrosy AP, Mehta C, Teerlink JR, Zannad F, O'Connor CM. Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. 2018. PMID: 30354535


  76. Di Tullio MR, Qian M, Thompson JLP, Labovitz AJ, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Lip GYH, Levin B, Mohr JP, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S. Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. 2018. PMID: 30015405


  77. Verma AK, Sun JL, Hernandez A, Teerlink JR, Schulte PJ, Ezekowitz J, Voors A, Starling R, Armstrong P, O'Conner CM, Mentz RJ. Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. 2018. PMID: 29781109


  78. Lee TC, Qian M, Lip GYH, Di Tullio MR, Graham S, Mann DL, Nakanishi K, Teerlink JR, Freudenberger RS, Sacco RL, Mohr JP, Labovitz AJ, Ponikowski P, Lok DJ, Estol C, Anker SD, Pullicino PM, Buchsbaum R, Levin B, Thompson JLP, Homma S, Ye S. Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). 2018. PMID: 30037426


  79. Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, Damman K, Pérez-Calvo JI, Voors AA. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. 2018. PMID: 29544928


  80. Metra M, Cotter G, Senger S, Edwards C, Cleland JG, Ponikowski P, Cursack GC, Milo O, Teerlink JR, Givertz MM, O'Connor CM, Dittrich HC, Bloomfield DM, Voors AA, Davison BA. Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data. 2018. PMID: 29748350


  81. Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, O'Connor CM, Mentz RJ. Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. 2018. PMID: 29525328


  82. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. 2018. PMID: 29495982


  83. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. 2018. PMID: 29483172


  84. Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, O'Connor CM, Teerlink JR, Zannad F, Solomon SD. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. 2018. PMID: 29464817


  85. Metra M, Davison BA, Gimpelewicz C, Carubelli V, Felker GM, Filippatos G, Greenberg BH, Hua TA, Liu Z, Pang PS, Ponikowski P, Severin TM, Voors AA, Wang Y, Cotter G, Teerlink JR. Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. 2018. PMID: 29306479


  86. Pokorney SD, Al-Khatib SM, Sun JL, Schulte P, O'Connor CM, Teerlink JR, Armstrong PW, Ezekowitz JA, Starling RC, Voors AA, Velazquez EJ, Hernandez AF, Mentz RJ. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. 2017. PMID: 29266564


  87. Collins SP, Levy PD, Fermann GJ, Givertz MM, Martindale JM, Pang PS, Storrow AB, Diercks DD, Michael Felker G, Fonarow GC, Lanfear DJ, Lenihan DJ, Lindenfeld JM, Frank Peacock W, Sawyer DM, Teerlink JR, Butler J. What's Next for Acute Heart Failure Research? 2017. PMID: 28990334


  88. Filippatos G, Farmakis D, Metra M, Cotter G, Davison BA, Felker GM, Greenberg BH, Hua TA, Pang PS, Ponikowski P, Qian M, Severin TA, Voors AA, Teerlink JR. Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. 2017. PMID: 28752374


  89. Cotter G, Davison BA, Butler J, Collins SP, Ezekowitz JA, Felker GM, Filippatos G, Levy PD, Metra M, Ponikowski P, Teerlink JR, Voors AA, Senger S, Bharucha D, Goin K, Soergel DG, Pang PS. Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. 2017. PMID: 28986703


  90. McDonald MA, Ashley EA, Fedak PWM, Hawkins N, Januzzi JL, McMurray JJV, Parikh VN, Rao V, Svystonyuk D, Teerlink JR, Virani S. Mind the Gap: Current Challenges and Future State of Heart Failure Care. 2017. PMID: 29111107


  91. Cotter G, Metra M, Davison BA, Jondeau G, Cleland JGF, Bourge RC, Milo O, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJV, Teerlink JR. Systolic blood pressure reduction during the first 24?h in acute heart failure admission: friend or foe? 2017. PMID: 28871621


  92. Pang PS, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Teerlink JR, Voors AA, Bharucha D, Goin K, Soergel DG, Felker GM. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). 2017. PMID: 28459958


  93. Teerlink JR, Qian M, Bello NA, Freudenberger RS, Levin B, Di Tullio MR, Graham S, Mann DL, Sacco RL, Mohr JP, Lip GYH, Labovitz AJ, Lee SC, Ponikowski P, Lok DJ, Anker SD, Thompson JLP, Homma S. Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial. 2017. PMID: 28774396


  94. Greene SJ, Hernandez AF, Dunning A, Ambrosy AP, Armstrong PW, Butler J, Cerbin LP, Coles A, Ezekowitz JA, Metra M, Starling RC, Teerlink JR, Voors AA, O'Connor CM, Mentz RJ. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. 2017. PMID: 28641792


  95. Sharma A, Demissei BG, Tromp J, Hillege HL, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Cotter G, Ezekowitz JA, Khan MAF, Voors AA. A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. 2017. PMID: 28639369


  96. Tromp J, Khan MAF, Mentz RJ, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, Bloomfield DM, Van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P. Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. 2017. PMID: 28624483


  97. Liu LCY, Valente MAE, Postmus D, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, Bloomfield DM, van Veldhuisen DJ, Hillege HL, van der Meer P, Voors AA. Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure. 2017. PMID: 28656542


  98. Teerlink JR, Metra M, Filippatos GS, Davison BA, Bartunek J, Terzic A, Gersh BJ, Povsic TJ, Henry TD, Alexandre B, Homsy C, Edwards C, Seron A, Wijns W, Cotter G. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. 2017. PMID: 28560782


  99. Gimpelewicz C, Metra M, Cleland JGF, Szecsödy P, Chang Wun CC, Boer-Martins L, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang P, Ponikowski P, Severin T, Voors AA, Teerlink JR. Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. 2017. PMID: 28760204


  100. Metra M, Teerlink JR. Heart failure. 2017. PMID: 28460827


  101. Teerlink JR, Voors AA, Ponikowski P, Pang PS, Greenberg BH, Filippatos G, Felker GM, Davison BA, Cotter G, Gimpelewicz C, Boer-Martins L, Wernsing M, Hua TA, Severin T, Metra M. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. 2017. PMID: 28452195


  102. Nakanishi K, Di Tullio MR, Qian M, Thompson JLP, Labovitz AJ, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Lip GYH, Levin B, Mohr JP, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S. Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure. 2017. PMID: 28419982


  103. Butler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade M. Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. 2017. PMID: 28356300


  104. Cleland JGF, Teerlink JR, Davison BA, Shoaib A, Metra M, Senger S, Milo O, Cotter G, Bourge RC, Parker JD, Jondeau G, Krum H, O'Connor CM, Torre-Amione G, van Veldhuisen DJ, McMurray JJV. Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (V 2017. PMID: 28296139


  105. Bartunek J, Terzic A, Davison BA, Filippatos GS, Radovanovic S, Beleslin B, Merkely B, Musialek P, Wojakowski W, Andreka P, Horvath IG, Katz A, Dolatabadi D, El Nakadi B, Arandjelovic A, Edes I, Seferovic PM, Obradovic S, Vanderheyden M, Jagic N, Petrov I, Atar S, Halabi M, Gelev VL, Shochat MK, Kasprzak JD, Sanz-Ruiz R, Heyndrickx GR, Nyolczas N, Legrand V, Guédès A, Heyse A, Moccetti T, Fernandez-Aviles F, Jimenez-Quevedo P, Bayes-Genis A, Hernandez-Garcia JM, Ribichini F, Gruchala M, Waldman SA, Teerlink JR, Gersh BJ, Povsic TJ, Henry TD, Metra M, Hajjar RJ, Tendera M, Behfar A, Alexandre B, Seron A, Stough WG, Sherman W, Cotter G, Wijns W. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. 2017. PMID: 28025189


  106. Demissei BG, Postmus D, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, van Veldhuisen DJ, Dittrich HC, Hillege HL, Voors AA. Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. 2017. PMID: 28251755


  107. Pang PS, Teerlink JR, Boer-Martins L, Gimpelewicz C, Davison BA, Wang Y, Voors AA, Severin T, Ponikowski P, Hua TA, Greenberg BH, Filippatos G, Felker GM, Cotter G, Metra M. Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. 2017. PMID: 28454809


  108. Singh A, Laribi S, Teerlink JR, Mebazaa A. Agents with vasodilator properties in acute heart failure. 2017. PMID: 28201723


  109. Filippatos G, Farmakis D, Metra M, Cotter G, Davison BA, Felker GM, Greenberg BH, Hua TA, Pang PS, Ponikowski P, Qian M, Severin TA, Voors AA, Teerlink JR. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. 2017. PMID: 28150186


  110. Demissei BG, Cotter G, Prescott MF, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Severin TM, Wang Y, Qian M, Teerlink JR, Metra M, Davison BA, Voors AA. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. 2017. PMID: 28133908


  111. Streng KW, Ter Maaten JM, Cleland JG, O'Connor CM, Davison BA, Metra M, Givertz MM, Teerlink JR, Ponikowski P, Bloomfield DM, Dittrich HC, Hillege HL, van Veldhuisen DJ, Voors AA, van der Meer P. Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. 2017. PMID: 28069685


  112. Ambrosy AP, Cerbin LP, Armstrong PW, Butler J, Coles A, DeVore AD, Dunlap ME, Ezekowitz JA, Felker GM, Fudim M, Greene SJ, Hernandez AF, O'Connor CM, Schulte P, Starling RC, Teerlink JR, Voors AA, Mentz RJ. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. 2017. PMID: 28034373


  113. Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. 2016. PMID: 27914656


  114. Meyer S, Teerlink JR, Metra M, Ponikowski P, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Hua TA, Severin T, Qian M, Voors AA. Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. 2016. PMID: 27838739


  115. Sato N, Lam CS, Teerlink JR, Greenberg BH, Tsutsui H, Oh BH, Zhang J, Lefkowitz M, Hua TA, Holbro T, Marshood M, Wang XL, Ge J. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. 2016. PMID: 27825893


  116. Tromp J, Ter Maaten JM, Damman K, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, van der Wal MH, Jaarsma T, van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P. Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). 2016. PMID: 27823598


  117. Matsue Y, van der Meer P, Damman K, Metra M, O'Connor CM, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Dittrich HC, Gansevoort RT, Bakker SJ, van der Harst P, Hillege HL, van Veldhuisen DJ, Voors AA. Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. 2016. PMID: 27658757


  118. Matsue Y, Ter Maaten JM, Struck J, Metra M, O'Connor CM, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Dittrich HC, van Veldhuisen DJ, van der Meer P, Damman K, Voors AA. Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. 2016. PMID: 27663098


  119. Wiklund I, Anatchkova M, Oko-Osi H, von Maltzahn R, Chau D, Malik FI, Patrick DL, Spertus J, Teerlink JR. Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program. 2016. PMID: 27629389


  120. Vegter EL, Schmitter D, Hagemeijer Y, Ovchinnikova ES, van der Harst P, Teerlink JR, O'Connor CM, Metra M, Davison BA, Bloomfield D, Cotter G, Cleland JG, Givertz MM, Ponikowski P, van Veldhuisen DJ, van der Meer P, Berezikov E, Voors AA, Khan MA. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. 2016. PMID: 27661412


  121. Greene SJ, Hernandez AF, Sun JL, Metra M, Butler J, Ambrosy AP, Ezekowitz JA, Starling RC, Teerlink JR, Schulte PJ, Voors AA, Armstrong PW, O'Connor CM, Mentz RJ. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 2016. PMID: 27623769


  122. Demissei BG, Postmus D, Liu LCY, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Edwards C, Givertz MM, Bloomfield DM, Dittrich HC, Voors AA, Hillege HL. Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. 2016. PMID: 27589047


  123. Collins SP, Levy PD, Martindale JL, Dunlap ME, Storrow AB, Pang PS, Albert NM, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hollander JE, Lanfear DE, Lenihan DJ, Lindenfeld JM, Peacock WF, Sawyer DB, Teerlink JR, Butler J. Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. 2016. PMID: 27286136


  124. Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Cotter G, Davison B, Cleland JG, Bloomfield DM, Hillege HL, van Veldhuisen DJ, Voors AA, Testani JM. Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. 2016. PMID: 27507112


  125. Ye S, Qian M, Zhao B, Buchsbaum R, Sacco RL, Levin B, Di Tullio MR, Mann DL, Pullicino PM, Freudenberger RS, Teerlink JR, Mohr JP, Graham S, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Lip GY, Thompson JL, Homma S. CHA2 DS2 -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. 2016. PMID: 27444219


  126. Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Teerlink J, McMurray JJV, Solomon SD. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. 2016. PMID: 27417000


  127. Psotka MA, von Maltzahn R, Anatchkova M, Agodoa I, Chau D, Malik FI, Patrick DL, Spertus JA, Wiklund I, Teerlink JR. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval. 2016. PMID: 27395351


  128. Tromp J, Meyer S, Mentz RJ, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P. Acute heart failure in the young: Clinical characteristics and biomarker profiles. 2016. PMID: 27448534


  129. Di Tullio MR, Qian M, Thompson JL, Labovitz AJ, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Lip GY, Levin B, Mohr JP, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S. Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial. 2016. PMID: 27354224


  130. Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. 2016. PMID: 27283779


  131. Collins SP, Levy PD, Martindale JL, Dunlap ME, Storrow AB, Pang PS, Albert NM, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hollander JE, Lanfear DJ, Lenihan DJ, Lindenfeld JM, Peacock WF, Sawyer DB, Teerlink JR, Butler J. Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. 2016. PMID: 27262665


  132. Ter Maaten JM, Valente MA, Damman K, Cleland JG, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Bloomfield DM, Cotter G, Davison B, Subacius H, van Veldhuisen DJ, van der Meer P, Hillege HL, Gheorghiade M, Voors AA. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. 2016. PMID: 27266853


  133. Psotka MA, Teerlink JR. Ivabradine: Role in the Chronic Heart Failure Armamentarium. 2016. PMID: 27217432


  134. Biegus J, Hillege HL, Postmus D, Valente MA, Bloomfield DM, Cleland JG, Cotter G, Davison BA, Dittrich HC, Fiuzat M, Givertz MM, Massie BM, Metra M, Teerlink JR, Voors AA, O'Connor CM, Ponikowski P. Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. 2016. PMID: 27170455


  135. Davison BA, Metra M, Senger S, Edwards C, Milo O, Bloomfield DM, Cleland JG, Dittrich HC, Givertz MM, O'Connor CM, Massie BM, Ponikowski P, Teerlink JR, Voors AA, Cotter G. Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. 2016. PMID: 27114058


  136. Pang PS, Teerlink JR, Voors AA, Ponikowski P, Greenberg BH, Filippatos G, Felker GM, Davison BA, Cotter G, Kriger J, Prescott MF, Hua TA, Severin T, Metra M. Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. 2016. PMID: 27039129


  137. Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JGF, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. 2016. PMID: 27012405


  138. Liu LC, Voors AA, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Chen Y, Greenberg BH, Ponikowski P, Pang PS, Prescott MF, Hua TA, Severin TM, Metra M. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. 2016. PMID: 27017514


  139. Metra M, Mentz RJ, Hernandez AF, Heizer GM, Armstrong PW, Clausell N, Corbalan R, Costanzo MR, Dickstein K, Dunlap ME, Ezekowitz JA, Howlett JG, Komajda M, Krum H, Lombardi C, Fonarow GC, McMurray JJ, Nieminen MS, Swedberg K, Voors AA, Starling RC, Teerlink JR, O'Connor CM. Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). 2016. PMID: 27108685


  140. Yoon J, Fonarow GC, Groeneveld PW, Teerlink JR, Whooley MA, Sahay A, Heidenreich PA. Patient and Facility Variation in Costs of VA Heart Failure Patients. 2016. PMID: 26970829


  141. Kato TS, Di Tullio MR, Qian M, Wu M, Thompson JL, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Lip GY, Levin B, Mohr JP, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S. Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure - Subanalysis of the WARCEF Trial. 2016. PMID: 26804607


  142. Samsky MD, Dunning A, DeVore AD, Schulte PJ, Starling RC, Tang WH, Armstrong PW, Ezekowitz JA, Butler J, McMurray JJ, Teerlink JR, Voors AA, Metra M, Mentz RJ, O'Connor CM, Patel CB, Hernandez AF. Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. 2015. PMID: 26707029


  143. Cotter G, Davison BA, Milo O, Bourge RC, Cleland JG, Jondeau G, Krum H, O'Connor CM, Metra M, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJ, Teerlink JR. Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. 2015. PMID: 26721775


  144. Liu LC, Dorhout B, van der Meer P, Teerlink JR, Voors AA. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. 2015. PMID: 26587768


  145. Demissei BG, Valente MA, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Givertz MM, Bloomfield DM, Dittrich H, van der Meer P, van Veldhuisen DJ, Hillege HL, Voors AA. Optimizing clinical use of biomarkers in high-risk acute heart failure patients. 2015. PMID: 26634889


  146. Demissei BG, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Davison B, Givertz MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Hillege HL, Voors AA, Cotter G. Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. 2015. PMID: 26666342


  147. Tietjens J, Teerlink JR. Serelaxin and acute heart failure. 2015. PMID: 26603680


  148. Bruno N, ter Maaten JM, Ovchinnikova ES, Vegter EL, Valente MA, van der Meer P, de Boer RA, van der Harst P, Schmitter D, Metra M, O'Connor CM, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Dittrich HC, Pinto YM, van Veldhuisen DJ, Hillege HL, Berezikov E, Voors AA. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. 2015. PMID: 26569364


  149. Freudenberger RS, Cheng B, Mann DL, Thompson JL, Sacco RL, Buchsbaum R, Sanford A, Pullicino PM, Levin B, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Di Tullio MR, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S. The first prognostic model for stroke and death in patients with systolic heart failure. 2015. PMID: 26549533


  150. Emmens JE, Ter Maaten JM, Matsue Y, Metra M, O'Connor CM, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Dittrich HC, Todd J, van Veldhuisen DJ, Hillege HL, Damman K, van der Meer P, Voors AA. Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. 2015. PMID: 26511274


  151. Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. 2015. PMID: 26403536


  152. Ovchinnikova ES, Schmitter D, Vegter EL, Ter Maaten JM, Valente MA, Liu LC, van der Harst P, Pinto YM, de Boer RA, Meyer S, Teerlink JR, O'Connor CM, Metra M, Davison BA, Bloomfield DM, Cotter G, Cleland JG, Mebazaa A, Laribi S, Givertz MM, Ponikowski P, van der Meer P, van Veldhuisen DJ, Voors AA, Berezikov E. Signature of circulating microRNAs in patients with acute heart failure. 2015. PMID: 26345695


  153. Cotter G, Voors AA, Prescott MF, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Milo O, Hua TA, Qian M, Severin TM, Teerlink JR, Metra M, Davison BA. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. 2015. PMID: 26333529


  154. Felker GM, Mentz RJ, Teerlink JR, Voors AA, Pang PS, Ponikowski P, Greenberg BH, Filippatos G, Davison BA, Cotter G, Prescott MF, Hua TA, Lopez-Pintado S, Severin T, Metra M. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. 2015. PMID: 26333655


  155. ter Maaten JM, Valente MA, Metra M, Bruno N, O'Connor CM, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Dittrich HC, van Veldhuisen DJ, Hillege HL, Damman K, Voors AA. A combined clinical and biomarker approach to predict diuretic response in acute heart failure. 2015. PMID: 26280875


  156. Butler J, Gheorghiade M, Kelkar A, Fonarow GC, Anker S, Greene SJ, Papadimitriou L, Collins S, Ruschitzka F, Yancy CW, Teerlink JR, Adams K, Cotter G, Ponikowski P, Felker GM, Metra M, Filippatos G. In-hospital worsening heart failure. 2015. PMID: 26235192


  157. Psotka MA, Teerlink JR. Cardiac myosin activators: up and coming. 2015. PMID: 26179667


  158. Felker GM, Metra M, Teerlink JR. Reply: Mode of Death Prevention by Serelaxin. 2015. PMID: 26139069


  159. Larsen PM, Teerlink JR. Team-based Care for Patients Hospitalized with Heart Failure. 2015. PMID: 26142635


  160. Ye S, Cheng B, Lip GY, Buchsbaum R, Sacco RL, Levin B, Di Tullio MR, Qian M, Mann DL, Pullicino PM, Freudenberger RS, Teerlink JR, Mohr JP, Graham S, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Thompson JL, Homma S. Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. 2015. PMID: 26189039


  161. Mentz RJ, Metra M, Cotter G, Milo O, McKendry C, Chiswell K, Davison BA, Cleland JG, Bloomfield DM, Dittrich HC, Fiuzat M, Ponikowski P, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. 2015. PMID: 26083764


  162. Carson PE, Anand IS, Win S, Rector T, Haass M, Lopez-Sendon J, Miller A, Teerlink JR, White M, McKelvie RS, Komajda M, Zile MR, McMurray JJ, Massie B. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). 2015. PMID: 25982110


  163. Fang JC, Ewald GA, Allen LA, Butler J, Westlake Canary CA, Colvin-Adams M, Dickinson MG, Levy P, Stough WG, Sweitzer NK, Teerlink JR, Whellan DJ, Albert NM, Krishnamani R, Rich MW, Walsh MN, Bonnell MR, Carson PE, Chan MC, Dries DL, Hernandez AF, Hershberger RE, Katz SD, Moore S, Rodgers JE, Rogers JG, Vest AR, Givertz MM. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. 2015. PMID: 25953697


  164. Davison BA, Metra M, Cotter G, Massie BM, Cleland JGF, Dittrich HC, Edwards C, Filippatos G, Givertz MM, Greenberg B, Ponikowski P, Voors AA, O'Connor CM, Teerlink JR. Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. 2015. PMID: 25951761


  165. Khazanie P, Heizer GM, Hasselblad V, Armstrong PW, Califf RM, Ezekowitz J, Dickstein K, Levy WC, McMurray JJ, Metra M, Tang WH, Teerlink JR, Voors AA, O'Connor CM, Hernandez AF, Starling R. Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. 2015. PMID: 26299226


  166. Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. 2015. PMID: 25850425


  167. McMurray J, Packer M, Desai A, Gong J, Greenlaw N, Lefkowitz M, Rizkala A, Shi V, Rouleau J, Solomon S, Swedberg K, Zile MR, Andersen K, Arango JL, Arnold M, Belohlávek J, Böhm M, Boytsov S, Burgess L, Cabrera W, Chen CH, Erglis A, Fu M, Gomez E, Gonzalez A, Hagege AA, Katova T, Kiatchoosakun S, Kim KS, Bayram E, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires F, Refsgaard J, Senni M, Sibulo AS, Silva-Cardoso J, Squire I, Starling RC, Vinereanu D, Teerlink JR, Wong R. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. 2015. PMID: 25416329


  168. Felker GM, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Soergel DG, Teerlink JR, Violin JD, Voors AA, Pang PS. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). 2015. PMID: 25650371


  169. Metra M, Cotter G, El-Khorazaty J, Davison BA, Milo O, Carubelli V, Bourge RC, Cleland JG, Jondeau G, Krum H, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Rainisio M, Kobrin I, McMurray JJ, Teerlink JR. Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. 2015. PMID: 25573829


  170. Teerlink JR, Alburikan K, Metra M, Rodgers JE. Acute decompensated heart failure update. 2015. PMID: 24251454


  171. Metra M, Mentz RJ, Chiswell K, Bloomfield DM, Cleland JG, Cotter G, Davison BA, Dittrich HC, Fiuzat M, Givertz MM, Lazzarini V, Mansoor GA, Massie BM, Ponikowski P, Teerlink JR, Voors AA, O'Connor CM. Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. 2014. PMID: 25431336


  172. Graham S, Ye S, Qian M, Sanford AR, Di Tullio MR, Sacco RL, Mann DL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Mohr JP, Labovitz AJ, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Thompson JL, Homma S. Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. 2014. PMID: 25426862


  173. Collins SP, Storrow AB, Levy PD, Albert N, Butler J, Ezekowitz JA, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hiestand B, Hollander JE, Lanfear DE, Pang PS, Peacock WF, Sawyer DB, Teerlink JR, Lenihan DJ. Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. 2014. PMID: 25423908


  174. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Belohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. 2014. PMID: 25403646


  175. Cotter G, Metra M, Davison BA, Senger S, Bourge RC, Cleland JG, Jondeau G, Krum H, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Milo O, Kobrin I, Rainisio M, McMurray JJ, Teerlink JR. Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. 2014. PMID: 25371147


  176. Dubin RF, Beatty AL, Teerlink JR, Schiller NB, Alokozai D, Johansen KL. Associations of tissue Doppler imaging with NT-proBNP and hs-TnT: a pilot study in end-stage renal disease. 2014. PMID: 24828699


  177. Felker GM, Teerlink JR, Butler J, Hernandez AF, Miller AB, Cotter G, Davison BA, Filippatos G, Greenberg BH, Ponikowski P, Voors AA, Hua TA, Severin TM, Unemori E, Metra M. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. 2014. PMID: 25301463


  178. Pullicino PM, Qian M, Sacco RL, Freudenberger R, Graham S, Teerlink JR, Mann D, Di Tullio MR, Ponikowski P, Lok DJ, Anker SD, Lip GY, Estol CJ, Levin B, Mohr JP, Thompson JL, Homma S. Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. 2014. PMID: 25300706


  179. Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G, Greenberg BH, Pang PS, Levin B, Hua TA, Severin T, Ponikowski P, Metra M. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. 2014. PMID: 25287144


  180. Collins S, Storrow AB, Albert NM, Butler J, Ezekowitz J, Felker GM, Fermann GJ, Fonarow GC, Givertz MM, Hiestand B, Hollander JE, Lanfear DE, Levy PD, Pang PS, Peacock WF, Sawyer DB, Teerlink JR, Lenihan DJ. Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. 2014. PMID: 25042620


  181. Khodjaev SD, Teerlink JR, Malik FI. Novel drug mechanisms in development for heart failure. 2014. PMID: 24793049


  182. Mentz RJ, Cotter G, Cleland JG, Stevens SR, Chiswell K, Davison BA, Teerlink JR, Metra M, Voors AA, Grinfeld L, Ruda M, Mareev V, Lotan C, Bloomfield DM, Fiuzat M, Givertz MM, Ponikowski P, Massie BM, O'Connor CM. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. 2014. PMID: 24771609


  183. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O'Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. 2014. PMID: 24720916


  184. van Deursen VM, Edwards C, Cotter G, Davison BA, Damman K, Teerlink JR, Metra M, Felker GM, Ponikowski P, Unemori E, Severin T, Voors AA. Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. 2014. PMID: 24642379


  185. Gheorghiade M, Vaduganathan M, Greene SJ, Mentz RJ, Adams KF, Anker SD, Arnold M, Baschiera F, Cleland JG, Cotter G, Fonarow GC, Giordano C, Metra M, Misselwitz F, Mühlhofer E, Nodari S, Frank Peacock W, Pieske BM, Sabbah HN, Sato N, Shah MR, Stockbridge NL, Teerlink JR, van Veldhuisen DJ, Zalewski A, Zannad F, Butler J. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. 2014. PMID: 23099992


  186. Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 2014. PMID: 24585267


  187. Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM, Greenberg BH, Hua T, Ponikowski P, Severin T, Unemori E, Voors AA, Metra M. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. 2013. PMID: 24316514


  188. Meyer S, van der Meer P, Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL, Voors AA. Sex-specific acute heart failure phenotypes and outcomes from PROTECT. 2013. PMID: 24259042


  189. Cleland JG, Chiswell K, Teerlink JR, Stevens S, Fiuzat M, Givertz MM, Davison BA, Mansoor GA, Ponikowski P, Voors AA, Cotter G, Metra M, Massie BM, O'Connor CM. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized W 2013. PMID: 24281134


  190. Givertz MM, Postmus D, Hillege HL, Mansoor GA, Massie BM, Davison BA, Ponikowski P, Metra M, Teerlink JR, Cleland JG, Dittrich HC, O'Connor CM, Cotter G, Voors AA. Renal function trajectories and clinical outcomes in acute heart failure. 2013. PMID: 24281137


  191. Dubin RF, Beatty AL, Teerlink JR, Schiller NB, Bolger AF, Alokozai D, Peralta CA, Johansen KL. Determinants of hemodialysis-induced segmental wall motion abnormalities. 2013. PMID: 24224868


  192. Metra M, Ponikowski P, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Hua TA, Severin T, Unemori E, Voors AA, Teerlink JR. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. 2013. PMID: 23999454


  193. Selby VN, Teerlink JR. What's new in the treatment of acute heart failure? 2013. PMID: 23881577


  194. Pullicino PM, Thompson JL, Sacco RL, Sanford AR, Qian M, Teerlink JR, Haddad H, Diek M, Freudenberger RS, Labovitz AJ, Di Tullio MR, Lok DJ, Ponikowski P, Anker SD, Graham S, Mann DL, Mohr JP, Homma S. Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. 2013. PMID: 23921215


  195. Homma S, Thompson JL, Sanford AR, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Massie BM, Labovitz AJ, Di Tullio MR, Gabriel AP, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD. Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial. 2013. PMID: 23881846


  196. Eapen ZJ, Reed SD, Li Y, Kociol RD, Armstrong PW, Starling RC, McMurray JJ, Massie BM, Swedberg K, Ezekowitz JA, Fonarow GC, Teerlink JR, Metra M, Whellan DJ, O'Connor CM, Califf RM, Hernandez AF. Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. 2013. PMID: 23770519


  197. Dubin RF, Teerlink JR, Schiller NB, Alokozai D, Peralta CA, Johansen KL. Association of segmental wall motion abnormalities occurring during hemodialysis with post-dialysis fatigue. 2013. PMID: 23743019


  198. Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Fang JC, Hernandez AF, Katz SD, Krishnamani R, Stough WG, Walsh MN, Butler J, Carson PE, Dimarco JP, Hershberger RE, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Starling RC. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 2013. PMID: 23743486


  199. Teerlink JR, Metra M. Not time to RELAX in acute heart failure - Authors' reply. 2013. PMID: 23706796


  200. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. 2013. PMID: 24621834


  201. van der Meer P, Postmus D, Ponikowski P, Cleland JG, O'Connor CM, Cotter G, Metra M, Davison BA, Givertz MM, Mansoor GA, Teerlink JR, Massie BM, Hillege HL, Voors AA. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. 2013. PMID: 23500313


  202. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. 2013. PMID: 23273292


  203. Mentz RJ, Hernandez AF, Stebbins A, Ezekowitz JA, Felker GM, Heizer GM, Atar D, Teerlink JR, Califf RM, Massie BM, Hasselblad V, Starling RC, O'Connor CM, Ponikowski P. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. 2012. PMID: 23159547


  204. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. 2012. PMID: 23141816


  205. Kivikko M, Nieminen MS, Pollesello P, Pohjanjousi P, Colucci WS, Teerlink JR, Mebazaa A. The clinical effects of levosimendan are not attenuated by sulfonylureas. 2012. PMID: 22928945


  206. Goodlin SJ, Wingate S, Albert NM, Pressler SJ, Houser J, Kwon J, Chiong J, Storey CP, Quill T, Teerlink JR. Investigating pain in heart failure patients: the pain assessment, incidence, and nature in heart failure (PAIN-HF) study. 2012. PMID: 23040113


  207. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R. Warfarin and aspirin in patients with heart failure and sinus rhythm. 2012. PMID: 22551105


  208. O'Connor CM, Mentz RJ, Cotter G, Metra M, Cleland JG, Davison BA, Givertz MM, Mansoor GA, Ponikowski P, Teerlink JR, Voors AA, Fiuzat M, Wojdyla D, Chiswell K, Massie BM. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. 2012. PMID: 22535795


  209. Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. 2012. PMID: 22464767


  210. Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, Lovett DH, Miller AB, Piña IL, Thomson S, Varosy PD, Zile MR, Cleland JG, Givertz MM, Metra M, Ponikowski P, Voors AA, Davison BA, Cotter G, Wolko D, Delucca P, Salerno CM, Mansoor GA, Dittrich H, O'Connor CM, Massie BM. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. 2012. PMID: 22339573


  211. Ponikowski P, Metra M, Teerlink JR, Unemori E, Felker GM, Voors AA, Filippatos G, Greenberg B, Teichman SL, Severin T, Mueller-Velten G, Cotter G, Davison BA. Design of the RELAXin in acute heart failure study. 2012. PMID: 22305830


  212. Stevenson WG, Hernandez AF, Carson PE, Fang JC, Katz SD, Spertus JA, Sweitzer NK, Tang WH, Albert NM, Butler J, Westlake Canary CA, Collins SP, Colvin-Adams M, Ezekowitz JA, Givertz MM, Hershberger RE, Rogers JG, Teerlink JR, Walsh MN, Stough WG, Starling RC. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. 2012. PMID: 22300776


  213. McCabe JM, Bhave PD, McGlothlin D, Teerlink JR. Running from her past: a case of rapidly progressive dyspnea on exertion. 2011. PMID: 22105198


  214. Majure DT, Teerlink JR. Update on the Management of Acute Decompensated Heart Failure. 2011. PMID: 21976129


  215. Milo-Cotter O, Cotter-Davison B, Lombardi C, Sun H, Bettari L, Bugatti S, Rund M, Metra M, Kaluski E, Kobrin I, Frey A, Rainisio M, McMurray JJ, Teerlink JR, Cotter-Davison G. Neurohormonal activation in acute heart failure: results from VERITAS. 2011. PMID: 21912122


  216. O'Connor CM, Fiuzat M, Lombardi C, Fujita K, Jia G, Davison BA, Cleland J, Bloomfield D, Dittrich HC, Delucca P, Givertz MM, Mansoor G, Ponikowski P, Teerlink JR, Voors AA, Massie BM, Cotter G, Metra M. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. 2011. PMID: 21900185


  217. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. 2011. PMID: 21856480


  218. Krum H, Teerlink JR. Medical therapy for chronic heart failure. 2011. PMID: 21856485


  219. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. 2011. PMID: 21856481


  220. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Wilson WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. 2011. PMID: 21732835


  221. Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, Teerlink JR, Greenberg BH, Filippatos G, Teichman SL, Metra M. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. 2011. PMID: 21622980


  222. Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, Cotter G, Weatherley BD, Ponikowski P, Teerlink JR, Cleland JG, O'Connor CM, Givertz MM. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylli 2011. PMID: 21545947


  223. Davison BA, Cotter G, Sun H, Chen L, Teerlink JR, Metra M, Felker GM, Voors AA, Ponikowski P, Filippatos G, Greenberg B, Teichman SL, Unemori E, Koch GG. Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. 2011. PMID: 21416190


  224. Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. 2011. PMID: 21388993


  225. Metra M, O'Connor CM, Davison BA, Cleland JG, Ponikowski P, Teerlink JR, Voors AA, Givertz MM, Mansoor GA, Bloomfield DM, Jia G, DeLucca P, Massie B, Dittrich H, Cotter G. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. 2011. PMID: 21388992


  226. Gheorghiade M, Pang PS, O'Connor CM, Prasad K, McMurray J, Teerlink JR, Fiuzat M, Sabbah H, Komajda M. Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. 2010. PMID: 21315202


  227. Milo-Cotter O, Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Edwards C, Weatherley BD, Greenberg B, Filippatos G, Unemori E, Teichman SL, Cotter G. Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. 2010. PMID: 21088400


  228. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. 2010. PMID: 20925544


  229. Cotter G, Voors AA, Weatherley BD, Pang PS, Teerlink JR, Filippatos G, Ponikowski P, Milo-Cotter O, Dittrich H, Teichman SL, Adams KF, Gheorghiade M, Metra M. Acute heart failure clinical drug development: from planning to proof of activity to phase III. 2010. PMID: 20881385


  230. Teerlink JR. Ivabradine in heart failure--no paradigm SHIFT…yet. 2010. PMID: 20801501


  231. Metra M, Teerlink JR, Felker GM, Greenberg BH, Filippatos G, Ponikowski P, Teichman SL, Unemori E, Voors AA, Weatherley BD, Cotter G. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. 2010. PMID: 20732868


  232. Peacock WF, Braunwald E, Abraham W, Albert N, Burnett J, Christenson R, Collins S, Diercks D, Fonarow G, Hollander J, Kellerman A, Gheorghiade M, Kirk D, Levy P, Maisel A, Massie BM, O'Connor C, Pang P, Shah M, Sopko G, Stevenson L, Storrow A, Teerlink J. National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. 2010. PMID: 20650354


  233. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. 2010. PMID: 20610207


  234. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: review of biology and potential role in treating heart failure. 2010. PMID: 20424993


  235. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. 2010. PMID: 20231531


  236. Metra M, Cleland JG, Weatherley BD, Dittrich HC, Givertz MM, Massie BM, O'Connor CM, Ponikowski P, Teerlink JR, Voors AA, Cotter G. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. 2010. PMID: 20228387


  237. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Gheorghiade M. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. 2010. PMID: 20233993


  238. Teerlink JR, Metra M, Zacà V, Sabbah HN, Cotter G, Gheorghiade M, Cas LD. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. 2009. PMID: 19876734


  239. de Lissovoy G, Fraeman K, Teerlink JR, Mullahy J, Salon J, Sterz R, Durtschi A, Padley RJ. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. 2009. PMID: 19582491


  240. Pang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC, Grinfeld L, Ouyang J, Udelson JE, Gheorghiade M. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. 2009. PMID: 19561338


  241. Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pang PS, Piña IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N. Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. 2009. PMID: 19464405


  242. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. 2009. PMID: 19329178


  243. Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, Felker GM, Metra M, Cotter G. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. 2008. PMID: 19101795


  244. Metra M, Teerlink JR, Voors AA, Felker GM, Milo-Cotter O, Weatherley B, Dittrich H, Cotter G. Vasodilators in the treatment of acute heart failure: what we know, what we don't. 2008. PMID: 19096932


  245. Beohar N, Erdogan AK, Lee DC, Sabbah HN, Kern MJ, Teerlink J, Bonow RO, Gheorghiade M. Acute heart failure syndromes and coronary perfusion. 2008. PMID: 18582629


  246. Ho JE, Teerlink JR. Role of tolvaptan in acute decompensated heart failure. 2008. PMID: 18510477


  247. Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, Peacock WF, Fonarow GC, Aldeen AZ, Kirk JD, Storrow AB, Tavares M, Mebazaa A, Roland E, Massie BM, Maisel AS, Komajda M, Filippatos G, Gheorghiade M. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. 2008. PMID: 18310669


  248. Hollenberg SM, Teerlink JR. Acute heart failure: emerging from the shadows. 2008. PMID: 18158468


  249. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. 2007. PMID: 17986694


  250. Shah SJ, Teerlink JR. Nesiritide: a reappraisal of efficacy and safety. 2007. PMID: 17266470


  251. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. 2007. PMID: 17291932


  252. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. 2006. PMID: 17158653


  253. Greenberg BH, Mehra M, Teerlink JR, Ordronneau P, McCollum D, Gilbert EM. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure. 2006. PMID: 17023233


  254. Packer M, Abraham WT, Mehra MR, Yancy CW, Lawless CE, Mitchell JE, Smart FW, Bijou R, O'Connor CM, Massie BM, Pina IL, Greenberg BH, Young JB, Fishbein DP, Hauptman PJ, Bourge RC, Strobeck JE, Murali S, Schocken D, Teerlink JR, Levy WC, Trupp RJ, Silver MA. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. 2006. PMID: 16750691


  255. Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. 2005. PMID: 16181825


  256. Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). 2005. PMID: 16084150


  257. Teerlink JR, Massie BM. Nesiritide and worsening of renal function: the emperor's new clothes? 2005. PMID: 15795361


  258. Hussein SJ, Teerlink JR. Novel Pharmacologic Therapy of Heart Failure. 2003. PMID: 12834569


  259. Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. 2003. PMID: 12849674


  260. O'Connor CM, Gattis WA, Adams KF, Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). 2003. PMID: 12742280


  261. Gheorghiade M, Adams KF, Gattis WA, Teerlink JR, Orlandi C, O'Connor CM. Surrogate end points in heart failure trials. 2003. PMID: 12594457


  262. Victal OA, Teerlink JR, Gaxiola E, Wallace AW, Najar S, Camacho DH, Gutierrez A, Herrera G, Zuniga G, Mercado-Rios F, Ratcliffe MB. Left ventricular volume reduction by radiofrequency heating of chronic myocardial infarction in patients with congestive heart failure. 2002. PMID: 11901042


  263. Ratcliffe MB, Wallace AW, Teerlink JR, Hong J, Salahieh A, Sung SH, Keung EC, Lee RJ. Radio frequency heating of chronic ovine infarct leads to sustained infarct area and ventricular volume reduction. 2000. PMID: 10838539


  264. Teerlink JR, Massie BM. The role of beta-blockers in preventing sudden death in heart failure. 2000. PMID: 10908095


  265. Teerlink JR, Massie BM. Beta-adrenergic blocker mortality trials in congestive heart failure. 1999. PMID: 10568667


  266. Teerlink JR, Foster E. Valvular heart disease in pregnancy. A contemporary perspective. 1998. PMID: 9742331


  267. Teerlink JR, Carteaux JP, Sprecher U, Löffler BM, Clozel M, Clozel JP. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. 1995. PMID: 7840293


  268. Teerlink JR, Breu V, Sprecher U, Clozel M, Clozel JP. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. 1994. PMID: 8261583


  269. Teerlink JR, Clozel M, Fischli W, Clozel JP. Temporal evolution of endothelial dysfunction in a rat model of chronic heart failure. 1993. PMID: 8335837


  270. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. 1991. PMID: 2035416